绝经期血管舒缩症状与血浆阿尔茨海默病生物标志物
MsBrain研究在2017至2020年纳入274名45至67岁晚期围绝经期或绝经后女性,通过24小时动态皮肤电导监测评估血管舒缩症状,并检测血浆阿尔茨海默病生物标志物。248名参与者的数据分析显示,客观评估的睡眠期间血管舒缩症状与较低的血浆淀粉样β42/淀粉样β40比值显著相关(β=-0.0010,标准误0.0004,P=0.018)。作者认为夜间血管舒缩症状可能是阿尔茨海默病风险女性的标志物,但关联是否因果尚不清楚。
要点
- 客观监测的睡眠期血管舒缩症状与较低血浆淀粉样β42/淀粉样β40比值显著相关。
- 该关联在进一步校正雌二醇和睡眠后仍显著。
- 作者认为夜间血管舒缩症状可能是阿尔茨海默病风险女性的标志物,但因果关系未知。
核心结论
- 夜间血管舒缩症状可能是阿尔茨海默病风险女性的标志物,但这些关联是否因果尚不清楚。
研究设计与样本
- MsBrain研究于2017年至2020年纳入274名45至67岁、有子宫且至少保留1个卵巢、处于晚期围绝经期或绝经后状态的社区居住女性。
- 排除标准包括神经系统疾病、手术绝经以及近期使用激素或非激素血管舒缩症状治疗。
- 采用24小时动态皮肤电导监测评估血管舒缩症状,使用单分子阵列(Simoa)技术检测血浆阿尔茨海默病生物标志物。
- 最终248名参与者纳入分析(平均年龄59.06岁;81%为白人;99%为绝经后状态)。
主要发现
- 客观评估的睡眠期间血管舒缩症状与显著较低的淀粉样β42/淀粉样β40比值相关(β=-0.0010,标准误0.0004,P=0.018,多变量模型),提示脑内淀粉样β病理负荷可能更大。
- 进一步校正雌二醇和睡眠后,该关联仍显著。
关键数值与推荐
- 血浆生物标志物包括淀粉样β42/淀粉样β40比值、磷酸化tau(181和231)、胶质纤维酸性蛋白和神经丝轻链。
- 线性回归模型校正了年龄、种族和民族、教育程度、体重指数和载脂蛋白E4状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying risk factors for Alzheimer disease in women is important as women compose two-thirds of individuals with Alzheimer disease. Previous work links vasomotor symptoms, the cardinal menopausal symptom, with poor memory performance and alterations in brain structure, function, and connectivity. These associations are evident when vasomotor symptoms are monitored objectively with ambulatory skin conductance monitors. OBJECTIVE: This study aimed to determine whether vasomotor symptoms are associated with Alzheimer disease biomarkers. STUDY DESIGN: Between 2017 and 2020, the MsBrain study enrolled 274 community-dwelling women aged 45 to 67 years who had a uterus and at least 1 ovary and were late perimenopausal or postmenopausal status. The key exclusion criteria included neurologic disorder, surgical menopause, and recent use of hormonal or nonhormonal vasomotor symptom treatment. Women underwent 24 hours of ambulatory skin conductance monitoring to assess vasomotor symptoms. Plasma concentrations of Alzheimer disease biomarkers, including amyloid β 42-to-amyloid β 40 ratio, phosphorylated tau (181 and 231), glial fibrillary acidic protein, and neurofilament light, were measured using a single-molecule array (Simoa) technology. Associations between vasomotor symptoms and Alzheimer disease biomarkers were assessed via linear regression models adjusted for age, race and ethnicity, education, body mass index, and apolipoprotein E4 status. Additional models adjusted for estradiol and sleep. RESULTS: A total of 248 (mean age, 59.06 years; 81% White; 99% postmenopausal status) of enrolled MsBrain participants contributed data. Objectively assessed vasomotor symptoms occurring during sleep were associated with significantly lower amyloid β 42/amyloid β 40, (beta, -.0010 [standard error, .0004]; P=.018; multivariable), suggestive of greater brain amyloid β pathology. The findings remained significant after additional adjustments for estradiol and sleep. CONCLUSION: Nighttime vasomotor symptoms may be a marker of women at risk of Alzheimer disease. It is yet unknown if these associations are causal.
引用
- Thurston RC, Maki P, Chang Y, et al. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. Am J Obstet Gynecol. 2023. PMID: 37939982. doi:10.1016/j.ajog.2023.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。